Biomarkers for personalizing omega-3 fatty acid dosing

Cancer Prevention Research

Volumn 7, Issue 10, 2014, Pages 1011-1022

  Jiang, Yan ^a   Djuric, Zora ^a   Sen, Ananda ^a   Ren, Jianwei ^a   Kuklev, Dmitry ^a   Waters, Ian ^a   Zhao, Lili ^b   Uhlson, Charis L ^c   Hong, Yu H ^a   Murphy, Robert C ^c   Normolle, Daniel P ^d   Smith, William L ^a   Brenner, Dean E ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; BIOLOGICAL MARKER; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; FISH OIL; LINOLEIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROSTAGLANDIN E2; PROSTAGLANDIN E3; 2-TERT-BUTYLHYDROQUINONE; FATTY ACID; HYDROQUINONE DERIVATIVE; ICOSANOID; LIPID; PHOSPHOLIPID; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASCENDING COLON; CANCER MODEL; CHRONIC INFLAMMATION; COLON CANCER; CONTROLLED STUDY; DESCENDING COLON; DIET SUPPLEMENTATION; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; INFANT; LIPID DIET; LOW DRUG DOSE; MALE; MATHEMATICAL MODEL; METABOLITE; NONHUMAN; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROSTAGLANDIN URINE LEVEL; RAT; RAT MODEL; TISSUE LEVEL; TRANSVERSE COLON; ANIMAL; BODY WEIGHT; CHEMISTRY; COLON; FISCHER 344 RAT; INFLAMMATION; MASS FRAGMENTOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY; TEMPERATURE; THEORETICAL MODEL; URINE;

ANIMALS; BIOMARKERS, TUMOR; BODY WEIGHT; COLON; DINOPROSTONE; EICOSANOIDS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FISH OILS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HYDROQUINONES; INFLAMMATION; LIPIDS; MALE; MODELS, THEORETICAL; PHOSPHOLIPIDS; RATS; RATS, INBRED F344; TANDEM MASS SPECTROMETRY; TEMPERATURE;

EID: 84907523707     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0134     Document Type: Article

References (49)

1. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294:914-23.
2. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005; 294:47-55.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
4. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
5. FitzGerald GA. Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: A mechanism-based approach. Am J Cardiol 2002;89:1D-2D.
6. Lanas A. Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Ital J Gastroenterol Hepatol 1999;31 Suppl 1:S37-S42.
7. Comba A, Pasqualini ME. Primers on molecular pathways - lipoxygenases: Their role as an oncogenic pathway in pancreatic cancer. Pancreatology 2009;9:724-8.
8. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
9. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, et al. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res 2010;3:829-38.
10. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15- lipoxygenase-1 expression in human colon cancers. Carcinogenesis 1999;20:1985-95.
11. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 2007;282:22254-66.
12. Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005;17:174-82.
13. Rao CV, Hirose Y, Indranie C, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-33.
14. Gravaghi C, La Perle KM, Ogrodwski P, Kang JX, Quimby F, Lipkin M, et al. Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. J Nutr Biochem 2011;22:360-5.
15. Kato T, Kolenic N, Pardini RS. Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr Cancer 2007;58: 178-87.
16. Yuan C, Sidhu RS, Kuklev DV, Kado Y, Wada M, Song I, et al. Cyclooxygenase allosterism: fatty acid mediated cross-talk between monomers of cyclooxygenase homodimers. J Biol Chem 2009;284: 10046-55.
17. Sharma NP, Dong L, Yuan C, Noon KR, Smith WL. Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol Pharmcol 2010;77:979-86.
18. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004;3:215-21.
19. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. PNAS 2006;103:15184-9.
20. Matsumoto K, Morita I, Hibino H, Murota S. Inhibitory effect of docosahexaenoic acid-containing phospholipids on 5-lipoxygenase in rat basophilic leukemia cells. Prostaglandins Leukot Essent Fatty Acids 1993;49:861-6.
21. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United kingdom: evidence of right- To left-sided biological gradients with implications for screening. Cancer Res 2010;70:5419-29.
22. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, et al. Differences between right- And left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 2008;23:418-23.
23. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45.
24. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012;3:107.
25. Kuklev DV, Hankin JA, Uhlson CL, Hong YH, Murphy RC, Smith WL. Major urinary metabolites of 6-keto-prostaglandin F2alpha in mice. J Lipid Res 2013;54:1906-14.
26. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75.
27. Neilson AP, Ren J, Hong YH, Sen A, Smith WL, Brenner DE, et al. Effect of fish oil on levels of R- And S-enantiomers of 5-, 12-, and 15- hydroxyeicosatetraenoic acids in mouse colonic mucosa. Nutr Cancer 2012;64:163-72.
28. Yang P, Felix E, Madden T, Fischer SM, Newman RA. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- And 3-series prostaglandins in cultured tumor cells. Analytical Biochem 2002;308:168-77.
29. Falardeau P, Oates JA, Brash AR. Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Analytical Biochem 1981;115: 359-67.
30. Djuric Z, Ren J, Blythe J, VanLoon G, Sen A. A Mediterranean dietary intervention in healthy American women changes plasma carotenoids and fatty acids in distinct clusters. Nutr Res 2009;29:156-63.
31. Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999;5:3942-7.
32. Gee JM, Watson M, Matthew JA, Rhodes M, Speakman CJ, Stebbings WS, et al. Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics. J Nutr 1999;129:1862-5.
33. Bartram HP, Gostner A, Reddy BS, Rao CV, Scheppach W, Dusel G, et al. Missing anti-proliferative effect of fish oil on rectal epithelium in healthy volunteers consuming a high-fat diet: potential role of the n-3:n-6 fatty acid ratio. Eur J Cancer Prev 1995; 4:231-7.
34. Broughton KS, Whelan J, Hardardottir I, Kinsella JE. Effect of increasing the dietary (n-3) to (n-6) polyunsaturated fatty acid ratio on murine liver and peritoneal cell fatty acids and eicosanoid formation. J Nutr 1991;121:155-64.
35. Zou H, Yuan C, Dong L, Sidhu RS, Hong YH, Kuklev DV, et al. Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res 2012; 53:1336-47.
36. Malkowski MG, Thuresson ED, Lakkides KM, Rieke CJ, Micielli R, Smith WL, et al. Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem 2001;276:37547-55.
37. Dong L, Sharma NP, Jurban BJ, Smith WL. Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer. J Biol Chem 2013;288:28641-55.
38. Yang P, Jiang Y, Fischer SM. Prostaglandin E3 metabolism and cancer. Cancer Lett 2014;348:1-11.
39. Boudreau MD, Chanmugam PS, Hart SB, Lee SH, Hwang DH. Lack of dose response by dietary n-3 fatty acids at a constant ratio of n-3 to n-6 fatty acids in suppressing eicosanoid biosynthesis from arachidonic acid. Am J Clin Nutr 1991;54:111-7.
40. Bartram HP, Gostner A, Kelber E, Dusel G, Scheppach W, Kasper H. Effect of dietary fish oil on fecal bile acid and neutral sterol excretion in healthy volunteers. Z Ernahrungswiss 1998;37 Suppl 1:139-41.
41. Bartram HP, Gostner A, Scheppach W, Reddy BS, Rao CV, Dusel G, et al. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology 1993;105:1317-22.
42. Anti M, Armelao F, Marra G, Percesepe A, Bartoli GM, Palozza P, et al. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 1994; 107:1709-18.
43. Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, Percesepe A, et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992; 103:883-91.
44. Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis 2007;22:765-76.
45. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, et al. Epoxy metabolites of docosa hexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. PNAS 2013;110:6530-5.
46. Stark KD. The percentage of n-3 highly unsaturated fatty acids in total HUFA as a biomarker for omega-3 fatty acid status in tissues. Lipids 2008;43:45-53.
47. Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 2004;64:6797-804.
48. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 2006;24:5010-6.
49. Kakutani S, Ishikura Y, Tateishi N, Horikawa C, Tokuda H, Kontani M, et al. Supplementation of arachidonic acid-enriched oil increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites and clinical parameters in Japanese healthy elderly individuals: A randomized controlled study. Lipids Health Dis 2011;10:241.